GlassScriptPhysician profile
Amy Lee Cabrera
NPI 1831454123
$1,295.57
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $161 · 2021: $40.83 · 2022: $90.65 · 2023: $276 · 2024: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $682.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $258.83 | 2019-2024 | Opdivo, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $216.73 | 2019-2024 | Tagrisso, Enhertu, Imfinzi |
| Amgen INC. | $110.72 | 2022-2024 | Xgeva, Lumakras, Vectibix |
| Janssen Pharmaceuticals, INC | $82.04 | 2019-2024 | Darzalex |
| Merck Sharp & Dohme LLC | $81.45 | 2023-2024 | Keytruda |
| Genentech USA, INC. | $78.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $63.98 | 2019 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $63.70 | 2020-2022 | |
| Clovis Oncology, INC. | $62.41 | 2019-2020 | |
| Glaxosmithkline, LLC. | $37.49 | 2024 | Ojjaara, Jemperli |
| Seagen INC. | $28.66 | 2019 | |
| Genzyme Corporation | $25.75 | 2020 | |
| Abbvie INC. | $25.00 | 2024 | |
| Pbg Puerto Rico LLC | $25.00 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $24.97 | 2024 | Libtayo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $24.89 | 2024 | Monjuvi, Pemazyre, Jakafi |
| Puma Biotechnology, INC. | $23.00 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $19.69 | 2019 | |
| Exelixis INC. | $16.94 | 2019 | |
| Pfizer Pharmaceuticals LLC | $12.87 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.